BioCentury | Oct 3, 2018
Politics & Policy

Phage display founders win Nobel for chemistry

...of Biosceptre International Ltd. (Cambridge, U.K.). He was also a scientific founder at antibody companies Cambridge Antibody Technology Group plc...
BioCentury | Sep 7, 2018
Financial News

Winter, Jackson, Ramakishnan, Balasubramaniam among co-founders of new U.K. fund Ahren

...Gregory Winter, Steve Jackson and Shankar Balasubramanian. Winter was a scientific founder at antibody companies Cambridge Antibody Technology Group plc...
BioCentury | Sep 4, 2018
Financial News

Winter, Jackson, Ramakishnan, Balasubramaniam among co-founders of new U.K. fund Ahren

...Gregory Winter, Steve Jackson and Shankar Balasubramanian. Winter was a scientific founder at antibody companies Cambridge Antibody Technology Group plc...
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

...LSE:VER) in 2003, which has market cap of £98.7 million ($128.1 million) • Disclosure scandal Cambridge Antibody Technology Group plc...
BioCentury | Jul 21, 2016
Strategy

Brexit of brains

...via M&A, blunting the growth of the ecosystem. Most notable were Celltech Group plc and Cambridge Antibody Technology Group plc...
BioCentury | Feb 24, 2014
Tools & Techniques

Bigger is better

...pharma's Genentech Inc. unit partnered with Ensemble in 2012 to discover macrocyclic drug candidates. AstraZeneca's Cambridge Antibody Technology Group plc...
BioCentury | Jan 13, 2014
Product Development

Niche play on TGF beta

...focal segmental glomerulosclerosis, which can lead to kidney failure. The mAb was originally discovered by Cambridge Antibody...
BioCentury | Oct 21, 2013
Strategy

MedImmune's warheads

...19, & Dec. 20, 2010). MedImmune is developing moxetumomab pasudotox , a legacy program from Cambridge Antibody Technology Group plc...
BioCentury | Sep 26, 2011
Clinical News

Fresolimumab regulatory update

...factor (TGF) beta completed a Phase I trial for the indication. In 2000, Genzyme and Cambridge Antibody...
BioCentury | Jul 11, 2011
Company News

AstraZeneca, Novartis other news

...AstraZeneca acquired the patents through its 2006 acquisition of Cambridge Antibody Technology. The pharma subsequently combined Cambridge Antibody...
Items per page:
1 - 10 of 653
BioCentury | Oct 3, 2018
Politics & Policy

Phage display founders win Nobel for chemistry

...of Biosceptre International Ltd. (Cambridge, U.K.). He was also a scientific founder at antibody companies Cambridge Antibody Technology Group plc...
BioCentury | Sep 7, 2018
Financial News

Winter, Jackson, Ramakishnan, Balasubramaniam among co-founders of new U.K. fund Ahren

...Gregory Winter, Steve Jackson and Shankar Balasubramanian. Winter was a scientific founder at antibody companies Cambridge Antibody Technology Group plc...
BioCentury | Sep 4, 2018
Financial News

Winter, Jackson, Ramakishnan, Balasubramaniam among co-founders of new U.K. fund Ahren

...Gregory Winter, Steve Jackson and Shankar Balasubramanian. Winter was a scientific founder at antibody companies Cambridge Antibody Technology Group plc...
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

...LSE:VER) in 2003, which has market cap of £98.7 million ($128.1 million) • Disclosure scandal Cambridge Antibody Technology Group plc...
BioCentury | Jul 21, 2016
Strategy

Brexit of brains

...via M&A, blunting the growth of the ecosystem. Most notable were Celltech Group plc and Cambridge Antibody Technology Group plc...
BioCentury | Feb 24, 2014
Tools & Techniques

Bigger is better

...pharma's Genentech Inc. unit partnered with Ensemble in 2012 to discover macrocyclic drug candidates. AstraZeneca's Cambridge Antibody Technology Group plc...
BioCentury | Jan 13, 2014
Product Development

Niche play on TGF beta

...focal segmental glomerulosclerosis, which can lead to kidney failure. The mAb was originally discovered by Cambridge Antibody...
BioCentury | Oct 21, 2013
Strategy

MedImmune's warheads

...19, & Dec. 20, 2010). MedImmune is developing moxetumomab pasudotox , a legacy program from Cambridge Antibody Technology Group plc...
BioCentury | Sep 26, 2011
Clinical News

Fresolimumab regulatory update

...factor (TGF) beta completed a Phase I trial for the indication. In 2000, Genzyme and Cambridge Antibody...
BioCentury | Jul 11, 2011
Company News

AstraZeneca, Novartis other news

...AstraZeneca acquired the patents through its 2006 acquisition of Cambridge Antibody Technology. The pharma subsequently combined Cambridge Antibody...
Items per page:
1 - 10 of 653